AIDA TO START PHASE II TRIALS OF CANCER TREATMENT

Aida Pharmaceuticals has received approval from Chinese regulatory authorities to begin Phase II clinical trials of the genetic cancer treatment Rh-Apo2L.

These trials will take place in approximately 20 hospitals in China and will analyze the effect of Rh-Apo2L on two types of tumors chosen from the following cancers: advanced inert lymphoma, malignant melanoma, soft tissue sarcoma, pancreatic cancer, kidney cancer, non-small-cell lung cancer and colorectal cancer. The trials will analyze the specific efficacy of Rh-Apo2L in approximately 100 patients. Additionally, the company will continue to analyze the dosage and effectiveness of the drug as well as other drugs' interactions with Rh-Apo2L.

"This potentially revolutionary cancer treatment has received a great deal of attention this year including awards and grants from the state and federal governments," Aida's Chairman Jin Biao said. "We believe that we have the resources and man power to finish Phase II and Phase III trials in order to bring Rh-Apo2L to market by 2008."

Rh-Apo2L is an anti-tumor biological agent developed by Shanghai Qiaer Biotechnology, a newly acquired subsidiary of Aida Pharmaceuticals. Rh-Apo2L is a broad-spectrum genetic cell apoptosis agent that the company expects to be used for the treatment of a variety of cancerous tumors.